Treatment of non-small cell lung cancer comes to the age of immunotherapy
10.11855/j.issn.0577-7402.2017.06.01
- VernacularTitle:非小细胞肺癌治疗新时代:免疫治疗
- Author:
Dongmei YUAN
;
Yong SONG
- Keywords:
lung cancer;
non-small cell;
immunotherapy;
immune checkpoint;
programmed death protein 1;
cytotoxic T-lymphocyte-associated protein 4
- From:
Medical Journal of Chinese People's Liberation Army
2017;42(6):483-487
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors have become an important alternative for advanced non-small cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted therapy. Monoclonal antibodies directed against immune checkpoint have shown better results in the application of first- or second-line treatment of NSCLC and for both squamous and non-squamous cell carcinoma patients, especially for those with positive PD-L1 tumor cells. Some comments will be made in present paper about the efficacy, biomarker, combined therapy and the resistant mechanism of immune checkpoint inhibitors.
